US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US 500 Enhanced Volatility Wtd ETF

72.81

+0.43090.60%

Post-market: 72.810.0003+0.00%16:04 EDT

Volume:4.65K

Turnover:337.73K

Market Cap:418.66M

PE:364.05

High:72.81

Open:72.64

Low:72.50

Close:72.38

Loading ...

Overview Company News Filings

Press Release: BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Under-fire NAB boss set to return to public eye amid turmoil

The Sydney Morning Herald

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Growth Stocks Down 10% or More to Buy Right Now

Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Press Release: Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Press Release: Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

Are Costco and Netflix About to Become Wall Street's Next Stock-Split Stocks?

Jennifer Wolfenbarger Joins Franklin Electric as Chief Financial Officer, Bringing Extensive Financial Leadership in Global Operations

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

2 Unstoppable Stocks to Buy With Great Upside Potential

Press Release: Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Sauce Labs Appoints Seasoned SaaS Executive Vinod Hariharan as Chief Financial Officer

ACCESS Newswire

Press Release: Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

Ridley Appoints CFO

MT Newswires Live

C-suite on demand: Is Singapore ready to embrace fractional work?

Press Release: Alector Provides Executive Leadership Update

Why Casey's General Stores Stock Skyrocketed This Week

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CFO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CFO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CFO\",,,,,undefined,":{"symbol":"CFO","market":"US","secType":"STK","nameCN":"VictoryShares US 500 Enhanced Volatility Wtd ETF","latestPrice":72.8097,"timestamp":1753300800000,"preClose":72.3788,"halted":0,"volume":4649,"hourTrading":{"tag":"盘后","latestPrice":72.81,"preClose":72.8097,"latestTime":"16:04 EDT","volume":3,"amount":218.43,"timestamp":1753301047720},"delay":0,"floatShares":5750000,"shares":5750000,"eps":0.2,"marketStatus":"Post-Mkt","change":0.4309,"latestTime":"07-23 17:17:41 EDT","open":72.6409,"high":72.8097,"low":72.5,"amount":337732.582,"amplitude":0.004279,"askPrice":76.34,"askSize":66,"bidPrice":69.35,"bidSize":66,"shortable":3,"etf":1,"ttmEps":0.2,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753315200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":72.3788,"sharesOutstanding":5750000,"nav":71.625744,"aum":411847775,"dividendRate":0.013048,"bidAskSpread":0.001146,"postHourTrading":{"tag":"盘后","latestPrice":72.81,"preClose":72.8097,"latestTime":"16:04 EDT","volume":3,"amount":218.43,"timestamp":1753301047720},"volumeRatio":0.644013,"impliedVol":0.0718,"impliedVolPercentile":0.756},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CFO\",,,,,undefined,":{"symbol":"CFO","floatShares":5750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.644013,"shares":5750000,"dividePrice":0.95,"high":72.8097,"amplitude":0.004279,"preClose":72.3788,"low":72.5,"week52Low":60.03,"pbRate":"--","week52High":74.0723,"institutionHeld":0,"latestPrice":72.8097,"eps":0.2,"divideRate":0.013048,"volume":4649,"delay":0,"ttmEps":0.2,"open":72.6409,"prevYearClose":68.94,"prevWeekClose":71.8847,"prevMonthClose":71.29,"prevQuarterClose":71.29,"fiveDayClose":71.2749,"twentyDayClose":70.49,"sixtyDayClose":66.01},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CFO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553253485","title":"Press Release: BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2553253485","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553253485?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:00","pubTimestamp":1753185600,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., July 22, 2025  -- BioVie Inc.  , a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors.\"Amy and Kameel each bring an extraordinary combination of strategic vision, operational excellence, and hands-on experience developing and commercializing therapies in complex neurological and chronic diseases,\" said Cuong Do, President and Chief Executive Officer  of BioVie Inc. \"As BioVie continues to advance bezisterim through Phase 2 trials for early Parkinson's disease and long COVID, and plans the next steps in clinical development in our Alzheimer's disease and ascites programs, their expertise will be invaluable in achieving our mission of transforming the treatment of these devastating conditions.\". These appointments come at a time of growing momentum for BioVie. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4022","CNS","BK4139","BIVI","CFO","IPO","CEO","MD","BK4135","BK4196"],"gpt_icon":0},{"id":"2552912284","title":"Under-fire NAB boss set to return to public eye amid turmoil","url":"https://stock-news.laohu8.com/highlight/detail?id=2552912284","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552912284?lang=en_us&edition=fundamental","pubTime":"2025-07-18 10:54","pubTimestamp":1752807240,"startTime":"0","endTime":"0","summary":"NAB has denied that chief executive Andrew Irvine is undergoing mentoring ahead of his first public appearance next week amid concerns raised by some of the bank’s investors about his behaviour and le","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/under-fire-nab-boss-set-to-return-to-public-eye-amid-turmoil-20250718-p5mfxb.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["ABA.AU","BK7139","XKO.AU","BK7023","XJO.AU","CFO.AU","CFO","BK7123","XAO.AU"],"gpt_icon":0},{"id":"2552431175","title":"Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2552431175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552431175?lang=en_us&edition=fundamental","pubTime":"2025-07-18 04:05","pubTimestamp":1752782700,"startTime":"0","endTime":"0","summary":"CHASKA, Minn., July  17, 2025  (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/17/3117599/23089/en/Lifecore-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4121","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","BK4112","CFO","IE00BGHQF748.EUR","CDMO","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","BK4212","BK4139","LFCR","BK4588","NDAQ"],"gpt_icon":0},{"id":"2552883944","title":"10 Growth Stocks Down 10% or More to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2552883944","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552883944?lang=en_us&edition=fundamental","pubTime":"2025-07-17 18:02","pubTimestamp":1752746520,"startTime":"0","endTime":"0","summary":"However, these promising growth stocks have yet to set new highs.Although they haven't kept pace with the S&P 500 recently, these stocks offer investors market-beating potential over the long term.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/17/10-growth-stocks-down-10-or-more-to-buy-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1804176565.USD","LU0823421416.USD","LU0345774631.USD","FCF","LU1861559042.SGD","LU2063271972.USD","BK4532","SHOP","IE00BD6J9T35.USD","LU2265009873.SGD","BK4211","LU1861558580.USD","BK4585","BK4551","BK4566","LU1720051108.HKD","LU1691799644.USD","DUOL","BK4204","IPO","IE0004445239.USD","CFO","LU0823434740.USD","03165","BK4524","BK4116","BK4528","BK4613","LU1720051017.SGD","LU0823421333.USD","LU0390134368.USD","BK4539","LU0345774391.USD","LU0823434583.USD","LU1734074674.USD","BK4588","BK4548","BK4147","LU0081259029.USD","BK4543","LU0097036916.USD","LU2357305700.SGD","LU1548497426.USD","ASML"],"gpt_icon":1},{"id":"2552510894","title":"Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2552510894","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552510894?lang=en_us&edition=fundamental","pubTime":"2025-07-17 13:05","pubTimestamp":1752728700,"startTime":"0","endTime":"0","summary":"Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/17/3116955/0/en/Novartis-Appoints-Mukul-Mehta-as-Chief-Financial-Officer-as-Harry-Kirsch-Retires-after-22-Years-with-the-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO"],"gpt_icon":0},{"id":"2551164854","title":"Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164854","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164854?lang=en_us&edition=fundamental","pubTime":"2025-07-15 19:30","pubTimestamp":1752579000,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., July  15, 2025  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/15/3115480/0/en/Iovance-Biotherapeutics-Appoints-Corleen-Roche-as-Chief-Financial-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","CFO","IOVA","BK4505","BK4139"],"gpt_icon":0},{"id":"2550405614","title":"Press Release: Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550405614","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550405614?lang=en_us&edition=fundamental","pubTime":"2025-07-10 16:40","pubTimestamp":1752136800,"startTime":"0","endTime":"0","summary":"REYKJAVIK, Iceland, July 10, 2025  -- Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer . Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, and healthcare. Linda will be based in Iceland. Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down to spend more time in the U.S. and prioritize time with his family. He will continue supporting Alvotech in an advisory capacity, to ensure a smooth transition.Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar sp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4224","R","BK4156","CFO","BK4171","FR","BK4022","BK4139","ALVO"],"gpt_icon":0},{"id":"2550465162","title":"Press Release: Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2550465162","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550465162?lang=en_us&edition=fundamental","pubTime":"2025-07-09 23:45","pubTimestamp":1752075900,"startTime":"0","endTime":"0","summary":"Strasbourg, France, July 9, 2025, 5:45 p.m. CET -- Transgene , a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board.Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization .The Board of Directors voted to appoint Emmanuelle Quilès to serve the remainder of Philippe Archinard's term, that is until the 2026 Annual Shareholders' Meeting. This appointment is effective from July 9, 2025.Dr. Alessandro Riva, MD, Chairman and CEO of Transgene, commented: \"On behalf of Transgene's entire Board and leadership team, I would like to ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO","BK4022","BK4595","STRK","BK4585","BK4516","BK4232","BK4588","BK4596","R","BK4023","BK4600"],"gpt_icon":1},{"id":"2549183375","title":"Are Costco and Netflix About to Become Wall Street's Next Stock-Split Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549183375","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549183375?lang=en_us&edition=fundamental","pubTime":"2025-07-08 15:06","pubTimestamp":1751958360,"startTime":"0","endTime":"0","summary":"There's more to picking out Wall Street's next blockbuster stock split than a high share price.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/08/costco-netflix-wall-street-next-stock-split-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1435385759.SGD","LU1548497426.USD","LU0471298777.SGD","NFLX","IE00B19Z9505.USD","LU1989764664.SGD","BK4155","LU0642271901.SGD","LU1316542783.SGD","LU2361045086.USD","LU0689472784.USD","LU0719512351.SGD","COST","SGXZ51526630.SGD","LU0823434583.USD","IE00B19Z8X17.USD","LU2168563687.JPY","LU2097829019.USD","CFO","BK4551","BK4504","IE00B5TLWC47.USD","LU0234572021.USD","LU0265550946.USD","LU0471298694.HKD","BK4550","LU0823434740.USD","LU1035775433.USD","LU0256863902.USD","BK4534","LU0082616367.USD","LU2168564149.EUR","LU2264538146.SGD","LU2360032135.SGD","IE0008368304.USD","LU1496350171.SGD","BK4588","LU1066053197.SGD","LU0417517546.SGD","LU2552382132.HKD","LU2168564495.EUR","LU1116320901.HKD","SGXZ99366536.SGD","LU0203201768.USD","LU1267930730.SGD","LU0256863811.USD","BK4566","LU1429558221.USD","LU0006306889.USD","LU2168564065.EUR"],"gpt_icon":1},{"id":"2549550709","title":"Jennifer Wolfenbarger Joins Franklin Electric as Chief Financial Officer, Bringing Extensive Financial Leadership in Global Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2549550709","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549550709?lang=en_us&edition=fundamental","pubTime":"2025-07-08 04:49","pubTimestamp":1751921340,"startTime":"0","endTime":"0","summary":"FORT WAYNE, Ind., July  07, 2025  (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE) announced today that Jennifer Wolfenbarger has been appointed Chief Financial Officer (CFO) and Chief A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3111350/11167/en/Jennifer-Wolfenbarger-Joins-Franklin-Electric-as-Chief-Financial-Officer-Bringing-Extensive-Financial-Leadership-in-Global-Operations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2229751404.USD","LU2089279066.USD","BK4161","FELE","CFO"],"gpt_icon":0},{"id":"2549346565","title":"Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2549346565","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549346565?lang=en_us&edition=fundamental","pubTime":"2025-07-07 20:00","pubTimestamp":1751889600,"startTime":"0","endTime":"0","summary":"TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a dif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110957/0/en/Allarity-Therapeutics-Announces-Appointment-of-Jeff-Ervin-as-Chief-Financial-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","LENZ",".IXIC","QID","QLD","PSQ","TQQQ","ALLR","MNQmain","BK4139","USJW.SI","SQQQ","CFO","USAW.SI","BK4539","NVIW.SI","ADHD","TSYW.SI","BK4007"],"gpt_icon":1},{"id":"2549392685","title":"BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2549392685","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549392685?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., July  07, 2025  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110894/29446/en/BioCryst-Appoints-Babar-Ghias-Chief-Financial-Officer-and-Head-of-Corporate-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO"],"gpt_icon":0},{"id":"2548956588","title":"2 Unstoppable Stocks to Buy With Great Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2548956588","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548956588?lang=en_us&edition=fundamental","pubTime":"2025-07-02 18:30","pubTimestamp":1751452200,"startTime":"0","endTime":"0","summary":"Amazon's investments in robotics could pay off big for shareholders.Roku is the leading connected TV platform in the U.S., positioning it to capture billions in digital advertising revenue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/02/2-unstoppable-stocks-buy-great-upside-potential/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4507","LU0203201768.USD","LU1366333091.USD","LU1069344957.HKD","LU1232071149.USD","LU1551013425.SGD","BK4581","LU0689472784.USD","IE00BMPRXN33.USD","ROKU","LU1153585028.USD","LU1823568750.SGD","IE00B3S45H60.SGD","BK4538","LU0683600562.USD","LU0312595415.SGD","IE0004445239.USD","LU2237957902.USD","LU0234570918.USD","AMZN","LU2065170008.USD","IE00B775H168.HKD","LU1934455277.USD","LU0642271901.SGD","LU2602419157.SGD","IE00BMPRXQ63.HKD","LU0320765059.SGD","LU1551013342.USD","BK4532","LU0107464264.USD","LU0128525929.USD","LU1880398554.USD","LU1435385759.SGD","LU1732800096.USD","LU0289941410.SGD","LU0820562030.AUD","LU1316542783.SGD","LU1035775433.USD","LU0823434740.USD","BK4527","LU0354030511.USD","LU2430703095.HKD","CFO","LU1244550577.SGD","LU2264538146.SGD","LU0234572021.USD","USAW.SI","LU2089283258.USD","BK4108","IE00B19Z8W00.USD"],"gpt_icon":1},{"id":"2548006789","title":"Press Release: Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2548006789","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548006789?lang=en_us&edition=fundamental","pubTime":"2025-07-01 20:05","pubTimestamp":1751371500,"startTime":"0","endTime":"0","summary":"Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies. Career focused on driving business growth and developing an integrated commercial strategy to deliver results. Mr. Jahr joins Outlook Therapeutics having most recently served as the Chief Commercial Officer for Sobi North America , where he oversaw commercial strategy, planning and execution excellence, which includes accountability for all marketing, sales, operations and market access activities. During his tenure at Sobi NA, Mr. Jahr led the immunology and hematology franchises, and three global development asset teams focused on preparing for regulatory submission, life cycle management and launch. Prior to his role at Sobi NA he served as General Manager & Vice President Head of International Markets at UCB Pharma SA ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","03160","BK4575","CEO","LU1242518931.SGD","TM","BK4555","BK4099","LU1064131342.USD","LU1316542783.SGD","OTLK","LU0390134368.USD","LU2098885051.SGD","IE00B5949003.HKD","LU1988902786.USD","LENZ","LU1852331112.SGD","BK4585","BK4566","LU1242518857.USD","LU0719512351.SGD","LU0979878070.USD","LU1303367103.USD","BK4007","LU2054465674.USD","LU2264538146.SGD","LU1923623000.USD","IE0004445239.USD","GFS","LU0081259029.USD","BK4554","BK4604","IE00BMPRXR70.SGD","LU2458330243.SGD","CFO","BK4141","BK4529","LU1880398554.USD","BK4614","BK4612","LU1880398471.USD","UCB","BK4139","LU2458330169.SGD","IE00BMPRXN33.USD","LU0056508442.USD","LU0823434583.USD","LU2360106780.USD"],"gpt_icon":1},{"id":"2546942779","title":"Sauce Labs Appoints Seasoned SaaS Executive Vinod Hariharan as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546942779","media":"ACCESS Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546942779?lang=en_us&edition=fundamental","pubTime":"2025-06-27 23:00","pubTimestamp":1751036400,"startTime":"0","endTime":"0","summary":"Appointment Signals Focus on Strategic Growth and Financial Rigor for Testing Cloud Leader. SAN FRANCISCO, CA / ACCESS Newswire / June 27, 2025 / Sauce Labs Inc., the leading platform for continuous quality, today announced the appointment of Vinod Hariharan as its new Chief Financial Officer . Hariharan brings over 15 years of SaaS financial leadership experience and an extensive background in guiding finance organizations through transformative, high-growth environments.Hariharan joins Sauce Labs from Totango, a cloud-based customer success platform, bringing a proven track record of driving financial strategy and operational excellence. He previously served as CFO at Alida, a cloud-based customer experience management platform, and has held key financial leadership roles at prominent technology companies including Marketo, Salesforce, Bazaarvoice, and PwC. His expertise will be central to scaling Sauce Labs' operations and financial strategy.Sauce Labs is the leading platform for AI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sauce-labs-appoints-seasoned-saas-150000182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1720051017.SGD","LU1720051108.HKD","LU1064131342.USD","BK4548","LU1791710400.SGD","IE00BQXX3F31.USD","LU2361044865.SGD","LU2458330169.SGD","LU0130102774.USD","BK4535","BK4538","LU0251131958.USD","LU0127658192.USD","LU2361045086.USD","LU0511384066.AUD","LU0198837287.USD","LU2265009873.SGD","LU0048573561.USD","IE00B19Z8X17.USD","LU0719512351.SGD","BK4532","LU2087625088.SGD","LU0106261372.USD","LU0082616367.USD","LU1989764748.USD","LU1989764664.SGD","LU0648001328.SGD","LU1804176565.USD","LU1823568750.SGD","LU1551013342.USD","BK4579","LU1791710582.SGD","LU0006306889.USD","LU2236285917.USD","CRM","LU0689626769.HKD","LU0792757196.USD","LU1316542783.SGD","LU2756315318.SGD","IE00BQXX3D17.EUR","LU2286300806.USD","BK4598","LU1951200564.SGD","LU2247934214.USD","LU1551013425.SGD","LU0980610538.SGD","LU0354030511.USD","BK4613","IE00B19Z8W00.USD","CFO"],"gpt_icon":0},{"id":"2546322377","title":"Press Release: Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546322377","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546322377?lang=en_us&edition=fundamental","pubTime":"2025-06-26 04:01","pubTimestamp":1750881660,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June 25, 2025  -- Maravai LifeSciences Holdings, Inc. , a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh \"Raj\" Asarpota has been appointed Executive Vice President  and Chief Financial Officer , effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.\"We thank Kevin for his commitment to Maravai and his leadership over the past eight years,\" said Susannah Gray, Audit Committee Chair, Maravai Board of Directors. \"He has played an important role in shaping the company's foundation, and we're grateful for his continued support in an advisory role during this transition. We're pleased to welcome Raj, whose deep industry experience and proven track record make him well-suited for this next chapter in Maravai's growth.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRVI","EVP","BK4121","CFO"],"gpt_icon":0},{"id":"2546259456","title":"Ridley Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2546259456","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546259456?lang=en_us&edition=fundamental","pubTime":"2025-06-25 07:10","pubTimestamp":1750806644,"startTime":"0","endTime":"0","summary":"Ridley  appointed Chris Opperman as chief financial officer , effective end of the year, according to a Wednesday filing with the Australian bourse.Opperman will succeed current CFO Richard Betts, who will step back from full-time executive roles, the filing said.Betts will remain with the company over the next 12 months to support the transition, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7117","CFO","RIC.AU","CFO.AU","BK7023"],"gpt_icon":0},{"id":"2544411038","title":"C-suite on demand: Is Singapore ready to embrace fractional work?","url":"https://stock-news.laohu8.com/highlight/detail?id=2544411038","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544411038?lang=en_us&edition=fundamental","pubTime":"2025-06-20 06:00","pubTimestamp":1750370400,"startTime":"0","endTime":"0","summary":"The gig economy has reached the top levels of organisations, with executives – known as ‘fractional leaders’ – offering their expertise without...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/opinion-features/c-suite-demand-singapore-ready-embrace-fractional-work","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/opinion-features/c-suite-demand-singapore-ready-embrace-fractional-work","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["PTHS","CHRO","CFO","BK4139"],"gpt_icon":0},{"id":"2543371486","title":"Press Release: Alector Provides Executive Leadership Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2543371486","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543371486?lang=en_us&edition=fundamental","pubTime":"2025-06-14 04:05","pubTimestamp":1749845100,"startTime":"0","endTime":"0","summary":"-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 --. SOUTH SAN FRANCISCO, Calif., June 13, 2025  -- Alector, Inc. , a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer , Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M.B.A., the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position.Neil Berkley joined Alector in March 2024 as Chief Business Officer, bringing more than two decades of experience i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CFO","ALEC","BK4139"],"gpt_icon":0},{"id":"2543549774","title":"Why Casey's General Stores Stock Skyrocketed This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2543549774","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543549774?lang=en_us&edition=fundamental","pubTime":"2025-06-13 01:38","pubTimestamp":1749749880,"startTime":"0","endTime":"0","summary":"Casey's General Stores is quietly the fifth-largest pizza chain in the United States.It continues to grow its geographic footprint beyond the Midwest, and is now in 20 states.Leaning on its ability to make shrewd acquisitions, Casey's growth story could still be in its early chapters.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/12/why-caseys-general-stores-skyrocketed-this-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CASY","CFO","BK4113"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":165,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CFO\",params:#limit:5,,,undefined,":[{"date":"2025-07-10","symbol":"CFO","amount":0.085627,"announcedDate":"2025-07-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-10","defaultRemindTime":1752154200000,"name":"VictoryShares US 500 Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-11","payableDate":"2025-07-10","currency":"USD","dateTimestamp":1752120000000,"payDate":"2025-07-11"},{"date":"2025-06-09","symbol":"CFO","amount":0.11262,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-09","defaultRemindTime":1749475800000,"name":"VictoryShares US 500 Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-10","payableDate":"2025-06-09","currency":"USD","dateTimestamp":1749441600000,"payDate":"2025-06-10"},{"date":"2025-05-08","symbol":"CFO","amount":0.03005,"announcedDate":"2025-05-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-08","defaultRemindTime":1746711000000,"name":"VictoryShares US 500 Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-09","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746676800000,"payDate":"2025-05-09"},{"date":"2025-04-10","symbol":"CFO","amount":0.09739,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US 500 Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CFO","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US 500 Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CFO\",market:\"US\",,,undefined,":[{"executeDate":"2015-09-22","recordDate":"2015-09-24","paymentDate":"2015-09-25","value":0.1092497,"currency":"USD"},{"executeDate":"2015-12-28","recordDate":"2015-12-30","paymentDate":"2015-12-31","value":0.1653246,"currency":"USD"},{"executeDate":"2016-03-08","recordDate":"2016-03-10","paymentDate":"2016-03-11","value":0.1177036,"currency":"USD"},{"executeDate":"2016-06-14","recordDate":"2016-06-16","paymentDate":"2016-06-17","value":0.1457861,"currency":"USD"},{"executeDate":"2016-09-07","recordDate":"2016-09-09","paymentDate":"2016-09-12","value":0.1089324,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CFO\",market:\"US\",delay:false,,,undefined,":{}}}